Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
Sales of Novo's Wegovy on Alibaba's Tmall e-commerce platform and JD.com were 260 million yuan ($38 million) in 2025, against 416 million ($61 million) for Innovent's Xinermei, investment bank Jefferies said in a note
Adv Protein Chem Struct Biol
Larger and more diverse patient cohorts are needed, lower dosages of semaglutide have to be tested, and follow-ups need to be conducted beyond 26 weeks.
Shravya Gurnurkar We are proud to have the opportunity to give you the smile of your dreams
9 Conclusion GLP-1 receptor agonists have emerged as revolutionary therapeutic agents in the treatment of T2DM and obesity, exhibiting significant effectiveness via their multi-faceted activities